DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its third quarter 2024 financial results on Wednesday, November 6, 2024, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-818 ...

Core Insights - Perrigo Company plc has announced a new brand partnership with Dr. Brown's to launch a portfolio of infant formula solutions under the Good Start® | Dr. Brown's™ brand, aimed at providing trusted nutrition for infants [1][2][4] Group 1: Partnership Details - The partnership combines the strengths of Good Start®, a trusted infant formula brand for over 50 years, and Dr. Brown's®, known for its pediatrician-recommended baby bottles [1][2] - The new product line will include Soothe Pro™, Gentle Pro™, and Soy-ease Pro™ infant formulas, all designed to address common feeding issues such as fussiness and gas [2][4] Group 2: Product Features - Soothe Pro™ is formulated with probiotic L. reuteri to help reduce fussiness from the first bottle, providing complete nutrition for babies experiencing gas and spit-ups [2][4] - Gentle Pro™ promotes easy digestion and softer stools, containing the probiotic B. lactis, similar to those found in breast milk [2][4] - Soy-ease Pro™ is a milk and lactose-free option made with 100% plant-based proteins, catering to babies with milk or lactose sensitivity [2][4] Group 3: Market Availability - The Good Start® | Dr. Brown's™ infant formulas are now available at major retailers including Walmart, Amazon, and Kroger, enhancing accessibility for parents [3][4]

Core Viewpoint - Perrigo Company plc has successfully closed a public offering of $715 million in 6.125% Senior Notes and €350 million in 5.375% Senior Notes, with total net proceeds estimated at approximately $1,076 million after expenses [1][2]. Group 1: Offering Details - The offering includes $715 million of USD Notes due 2032 and €350 million of Euro Notes due 2032, both guaranteed on a senior unsecured basis by Perrigo and its subsidiaries [1]. - The net proceeds from the offering will be used to redeem all of the Issuer's 4.375% Senior Notes due 2026 and to prepay a portion of the Term B Loans under Perrigo's credit facilities [2]. Group 2: Management and Regulatory Information - The offering is conducted under an effective shelf registration statement filed with the Securities and Exchange Commission, and will be made via a prospectus supplement [3]. - BofA Securities, J.P. Morgan, Wells Fargo Securities, Morgan Stanley, and HSBC are the joint book-running managers for the USD Notes, while BofA Securities, HSBC, and J.P. Morgan manage the Euro Notes [2]. Group 3: Company Overview - Perrigo Company plc is a leading provider of Consumer Self-Care Products and over-the-counter health and wellness solutions aimed at enhancing individual well-being [4].

DUBLIN, Sept. 12, 2024 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO) today announced the pricing of a registered public offering by Perrigo Finance Unlimited Company, an indirect wholly-owned finance subsidiary of Perrigo (the "Issuer"), of $715 million aggregate principal amount of the Issuer's 6.125% Senior Notes due 2032 (the "USD Notes") and €350 million aggregate principal amount of the Issuer's 5.375% Senior Notes due 2032 (the "Euro Notes" and together with the USD Not ...

Atkinson joins Perrigo from Haleon plc, where he previously served as Interim General CounselDUBLIN, Sept. 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Charles Atkinson as Executive Vice President, General Counsel and Secretary. He is a skilled lawyer with nearly 25 years of experience, mostly within the regulated consumer self-care industry.President and CEO Patrick Lockwood-Taylor commented, "I am ver ...

Core Viewpoint - Perrigo Company plc is set to present at the Piper Sandler Growth Frontiers Conference on September 10, 2024, highlighting its position as a leading provider of Consumer Self-Care Products [1][2] Company Overview - Perrigo Company plc (NYSE: PRGO) specializes in Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions aimed at enhancing individual well-being [2] Event Details - The presentation will be conducted by President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra, scheduled for 10:00 AM CDT [1]

DUBLIN, Aug. 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer. In this newly created position, Dr. Ball will be responsible for an enterprise-wide marketing strategy that incorporates deep understanding of consumer needs and translates those into winning brand strategies, tactics, and actions. He will also evaluate untapped mark ...

Financial Data and Key Metrics Changes - Organic net sales declined by 9.1%, impacted by a nearly 7 percentage point decline from infant formula and a 4 percentage point decline from upper respiratory and pain & sleep aid categories, partially offset by a 1.7 percentage point growth from the rest of the business [14][24] - Gross and operating margins expanded by 190 basis points and 160 basis points year-over-year, with sequential expansion of over 400 basis points compared to Q1 2024 [14][27] - Second quarter EPS was $0.53, down $0.10 from the previous year, primarily due to a $0.09 discrete tax benefit in the prior year and a $0.14 impact from infant formula [15][24] Business Line Data and Key Metrics Changes - In the CSCI segment, organic growth was 1%, with strong growth of 4.5 percentage points across the rest of the segment, offsetting a 3.5 percentage point headwind from lower seasonal demand and supply constraints [25] - In the CSCA segment, organic net sales declined by 15%, with a 10.8 percentage point impact from infant formula and a 4.4 percentage point impact from upper respiratory and pain & sleep aids [26] - OTC brands grew more than 40%, driven by Opill, Nasonex, and Mederma [26] Market Data and Key Metrics Changes - Cough/cold and allergy volume consumption declined mid to high single digits due to lower seasonal incidences and inventory changes at U.S. retail customers, leading to a 2.5 percentage point unfavorable impact on the 2024 net sales outlook [11] - The U.S. store brand business faced a 1.5 percentage point headwind due to walking away from a dilutive business, but new business wins are expected to offset this in 2025 [13][29] Company Strategy and Development Direction - The company is focused on enhancing its quality assured infant formula network and expects profitability to recover faster than originally anticipated [11][19] - Strategic work is ongoing to identify high-potential growth opportunities, with a focus on consumer-led innovation and brand building capabilities [7][21] - The company aims to achieve operating margin targets of 14% to 16% by the end of 2024, with significant progress in margin expansion noted [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of the infant formula business and the overall strength of the diversified business model to absorb sales impacts [11][21] - The company anticipates a significant earnings uplift in the second half of 2024, driven by the recovery of the infant formula business and lower operating expenses from Project Energize [30] - Management remains optimistic about the growth opportunities in the self-care market and the company's ability to deliver long-term value [21][30] Other Important Information - The company expects to deliver $25 million in incremental HRA synergies and has achieved $53 million in gross savings from Project Energize in the first half of the year [18] - Cash on the balance sheet at the end of Q2 was $543 million, with year-to-date operating cash flow at $8 million [27][28] Q&A Session Summary Question: Can you elaborate on the lost customer and its impact? - Management confirmed that the lost business was margin-dilutive and that new contracts won will offset the revenue loss, with a more margin-accretive profile [34][36] Question: How confident is the company in the recovery of the nutritional business? - Management expressed confidence in the successful execution of remediation efforts and the return to normal manufacturing operations [37][38] Question: What are the main drivers behind the guidance reduction? - The guidance reduction is primarily due to lower seasonal demand and U.S. retailer destocking, with SKU rationalization already factored into expectations [43][45] Question: What are the expectations for 2025? - Management expects a significant recovery in 2025, particularly in the infant formula segment, and anticipates that the impacts seen in the first half of 2024 will not repeat [46][48] Question: How is the company managing inventory levels for cough and cold products? - Management views the current inventory adjustments as a one-time occurrence and anticipates a need to replenish stocks in the upcoming cough and cold season [56]

Perrigo Company plc (PRGO) reported adjusted earnings of 53 cents per share in the second quarter of 2024, beating the Zacks Consensus Estimate of 48 cents. Earnings were down 15.9% year over year due to discrete tax benefits of nine cents per share in the year-ago period and a negative financial impact of 14 cents from infant formula. Net sales declined 10.7% year over year to $1.07 billion, missing the Zacks Consensus Estimate of $1.13 billion. The downside was due to lower net sales of infant formula and ...

Core Insights - Perrigo reported $1.07 billion in revenue for the quarter ended June 2024, reflecting a year-over-year decline of 10.7% [1] - The EPS for the same period was $0.53, down from $0.63 a year ago, but exceeded the consensus estimate of $0.48 by 10.42% [1] - The revenue fell short of the Zacks Consensus Estimate of $1.13 billion by 5.79% [1] Revenue Performance - Net Sales- Consumer Self-Care Americas (CSCA) reached $634.10 million, below the average estimate of $675.46 million, marking a year-over-year decline of 15.5% [3] - Net Sales- Consumer Self-Care International (CSCI) totaled $431.30 million, compared to the average estimate of $455.56 million, representing a decline of 2.5% year over year [4] - Net Sales- CSCA- Oral care was $73.20 million, slightly above the estimated $72.11 million, but down 4.8% from the previous year [5] - Net Sales- CSCA- Nutrition was $86.10 million, exceeding the estimate of $73.56 million, but showing a significant decline of 47.8% year over year [6] - Net Sales- CSCA- Healthy Lifestyle reached $69.10 million, slightly below the average estimate of $69.83 million, with a year-over-year increase of 2.7% [7] - Net Sales- CSCA- Upper Respiratory was $118.80 million, below the average estimate of $137.02 million, reflecting a decline of 13.7% year over year [8] Profit Metrics - Gross Profit- Consumer Self-Care International- Adjusted (CSCI) was $231.30 million, slightly below the average estimate of $236.90 million [9] - Gross Profit- Consumer Self-Care Americas- Adjusted (CSCA) totaled $201.30 million, compared to the average estimate of $209.90 million [10] Stock Performance - Shares of Perrigo have returned +7.6% over the past month, while the Zacks S&P 500 composite experienced a -0.4% change [11] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [11]